HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,955.00
-50.00 (-1.25%)
At close: Feb 6, 2026
-62.04%
Market Cap481.91B -62.9%
Revenue (ttm)114.33B +147.1%
Net Income-178.33B
EPS-1,434.56
Shares Out121.85M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume405,227
Average Volume756,421
Open3,960.00
Previous Close4,005.00
Day's Range3,845.00 - 3,990.00
52-Week Range3,105.00 - 11,940.00
Beta-0.06
RSI42.34
Earnings DateMar 19, 2026

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements